Tags

Type your tag names separated by a space and hit enter

Safety of MF59 adjuvant.
Vaccine. 2008 Jun 19; 26(26):3209-22.V

Abstract

The need to enhance the immunogenicity of purified subunit antigens has prompted the development of new adjuvants. The adjuvant emulsion MF59 has been tested in animals in combination with different antigens and finally evaluated in humans. It was licensed after the successful outcome of preclinical and clinical testing. This paper summarizes the main characteristics of the MF59 adjuvant, including animal testing, clinical experience with various vaccines, and information from current postmarketing surveillance data. This review supports the hypothesis that MF59 is a safe adjuvant for human use.

Authors+Show Affiliations

Novartis Vaccines and Diagnostics, Marburg, Germany. viola.schultze@novartis.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18462843

Citation

Schultze, Viola, et al. "Safety of MF59 Adjuvant." Vaccine, vol. 26, no. 26, 2008, pp. 3209-22.
Schultze V, D'Agosto V, Wack A, et al. Safety of MF59 adjuvant. Vaccine. 2008;26(26):3209-22.
Schultze, V., D'Agosto, V., Wack, A., Novicki, D., Zorn, J., & Hennig, R. (2008). Safety of MF59 adjuvant. Vaccine, 26(26), 3209-22. https://doi.org/10.1016/j.vaccine.2008.03.093
Schultze V, et al. Safety of MF59 Adjuvant. Vaccine. 2008 Jun 19;26(26):3209-22. PubMed PMID: 18462843.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Safety of MF59 adjuvant. AU - Schultze,Viola, AU - D'Agosto,Vicente, AU - Wack,Andreas, AU - Novicki,Deborah, AU - Zorn,Juergen, AU - Hennig,Renald, Y1 - 2008/04/21/ PY - 2007/07/30/received PY - 2008/03/12/revised PY - 2008/03/24/accepted PY - 2008/5/9/pubmed PY - 2008/9/10/medline PY - 2008/5/9/entrez SP - 3209 EP - 22 JF - Vaccine JO - Vaccine VL - 26 IS - 26 N2 - The need to enhance the immunogenicity of purified subunit antigens has prompted the development of new adjuvants. The adjuvant emulsion MF59 has been tested in animals in combination with different antigens and finally evaluated in humans. It was licensed after the successful outcome of preclinical and clinical testing. This paper summarizes the main characteristics of the MF59 adjuvant, including animal testing, clinical experience with various vaccines, and information from current postmarketing surveillance data. This review supports the hypothesis that MF59 is a safe adjuvant for human use. SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/18462843/Safety_of_MF59_adjuvant_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(08)00386-1 DB - PRIME DP - Unbound Medicine ER -